Epibiotech Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-5,058	-3,195
Depreciation & Amortization	743.99	373.93
Loss (Gain) From Sale of Assets	38.21	15.71
Other Operating Activities	0	-30.21
Change in Accounts Receivable	51.12	-48.44
Change in Inventory	-23.74	2.08
Change in Accounts Payable	-	-21.02
Change in Income Taxes	-0.88	-
Change in Other Net Operating Assets	-175.77	79.49
Operating Cash Flow	-4,425	-2,824
Capital Expenditures	-699.36	-1,745
Sale (Purchase) of Intangibles	-	-10
Sale (Purchase) of Real Estate	-	-13.59
Investment in Securities	4,012	-3,665
Other Investing Activities	-30	-165.98
Investing Cash Flow	3,283	-5,600
Long-Term Debt Repaid	-66.72	-300
Net Debt Issued (Repaid)	-66.72	-300
Issuance of Common Stock	1,543	10,220
Other Financing Activities	60	-
Financing Cash Flow	1,536	9,920
Miscellaneous Cash Flow Adjustments	-0	-0
Net Cash Flow	393.92	1,496
Free Cash Flow	-5,124	-4,569
Free Cash Flow Margin	-1139.68%	-1177.98%
Free Cash Flow Per Share	-3004.95	-2695.24
Levered Free Cash Flow	-2,490	-
Unlevered Free Cash Flow	-2,433	-
Change in Net Working Capital	-671.45	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.